Skip to main content
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. — Investor Relations & Filings

Ticker · JBIO ISIN · US0080641071 US Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2021-06-21 Regulatory Filings
Country US United States of America
Listing US JBIO

About Jade Biosciences, Inc.

https://jadebiosciences.com/

Jade Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, inflammation, and immunology. The company aims to create transformative, disease-modifying treatments to address significant unmet medical needs and redefine the standard of care. Its pipeline features novel biologics, with the lead candidate, JADE101, being developed for the treatment of immunoglobulin A nephropathy (IgAN). JADE101 is an inhibitor of the cytokine APRIL (A PRoliferation-Inducing Ligand). The company's programs are based on discovery-stage assets licensed from Paragon Therapeutics.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-06-21 English
FORM S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, which is a regulatory filing used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the registration, indemnification of directors and officers, recent sales of unregistered securities, and other disclosures relevant to the registration process. This is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not merely an announcement but a substantive filing amendment.
2021-06-17 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a law firm to the SEC regarding comments on a confidential draft Registration Statement on Form S-1 for Aerovate Therapeutics, Inc. It discusses revisions to the Registration Statement, clinical trial data, regulatory guidance, risk factors, use of proceeds, and stock valuation disclosures. The presence of the Form S-1 draft and the nature of the content indicate this is related to a registration statement for an initial public offering or similar securities offering. This is not a financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on a registration statement. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement, but a substantive regulatory correspondence.
2021-06-09 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for an initial public offering (IPO) or other public offerings. It contains detailed information about the company, its business, financial data, risk factors, management discussion and analysis, executive compensation, and other disclosures required for a securities offering. This is not an annual report, earnings release, or any other type of financial report but a registration statement for capital raising purposes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual filing, not just an announcement or certification. Hence, the correct classification is CAP with high confidence.
2021-06-09 English
Regulatory Filings 2021
Regulatory Filings
2021-06-02 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement confidentially submitted to the SEC by Aerovate Therapeutics, Inc. It is a draft registration statement under the Securities Act of 1933, used for registering securities for an initial public offering (IPO) or other public offerings. The text includes detailed information about the company, its business, management, financial data, risk factors, and offering details. This type of filing is a capital markets document related to fundraising and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-05-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.